The late effects of cis-platinum on renal function

Eur J Cancer Clin Oncol. 1989 Feb;25(2):185-9. doi: 10.1016/0277-5379(89)90006-0.

Abstract

The combination of bleomycin, etoposide and cis-platinum (BEP) is an effective treatment for germ cell tumours. To help define the role of recently developed non-nephrotoxic analogues of cis-platinum we have analysed the long term renal damage caused by this agent. We report on 22 patients studied 8-60 months following BEP chemotherapy. In the 17 cases with no pre-chemotherapy renal impairment there was a fall in mean glomerular filtration rate from 132 ml/min (95% confidence interval 123, 141) pre-chemotherapy to 103 ml/min (95% confidence interval 94, 113) on late follow up. The overall pattern is one of initial fall of glomerular filtration rate during chemotherapy, and no consistent evidence of late recovery or further deterioration; considerable individual variation is observed.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bleomycin / administration & dosage
  • Cisplatin / administration & dosage
  • Cisplatin / adverse effects*
  • Etoposide / administration & dosage
  • Glomerular Filtration Rate / drug effects
  • Humans
  • Kidney / drug effects*
  • Male
  • Middle Aged
  • Teratoma / drug therapy
  • Testicular Neoplasms / drug therapy*
  • Time Factors

Substances

  • Bleomycin
  • Etoposide
  • Cisplatin

Supplementary concepts

  • BEP protocol